TriCAR Vector Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs, a leader in the field for over two decades, introduces a revolutionary advancement in cellular immunotherapy - the TriCAR vector platform. TriCAR vectors boast a unique Tri-functional T Cell Engager (TriTE) construct that represents an evolution in the design of CAR-T therapies. At the heart of this innovation lies the TriTE construct, which distinguishes TriCAR vectors from conventional CAR-T approaches. TriTE is engineered to equip CAR-T cells with three distinct functionalities, allowing for a multi-pronged attack on cancer cells. This groundbreaking technology unlocks new dimensions of efficacy and precision in cancer immunotherapy.

Fig.1 The structure of a TriTE antibody and the way it connects T cells to cancer cells.¹

TriCAR Structure and Design

The TriTE construct within TriCAR vectors is a marvel of molecular engineering. It comprises three critical components:

Targeting Domain

The first component of the TriTE construct is the targeting domain. This domain determines which antigens the TriCAR-T cells will recognize and engage with. Unlike traditional CAR-T therapies that typically target a single antigen, TriCAR vectors incorporate three targeting domains, enabling these cells to recognize multiple antigens simultaneously.

Activation Domain

The activation domain of the TriTE construct is responsible for initiating intracellular signaling upon antigen recognition. It triggers a cascade of events within the CAR-T cell, leading to T-cell activation and cytotoxicity. In TriCAR vectors, this domain is finely tuned to ensure rapid and potent immune responses.

Tri-functional Engagement

The most distinctive feature of the TriTE construct is its tri-functional engagement capability. In addition to targeting cancer cells, the TriTE construct has the unique ability to engage other immune cells, such as natural killer (NK) cells and macrophages. This engagement leads to a coordinated immune response against the tumor, amplifying the therapeutic effect.

Advantages Over Traditional CAR-T Vectors

TriCAR vectors offer several distinct advantages over their traditional CAR-T counterparts.

Enhanced Targeting
TriCAR vectors can target multiple antigens simultaneously, making them highly effective against tumors with heterogeneous antigen expression. This versatility broadens their applicability across a wide range of cancer types.
Reduced Relapse Rates
By targeting multiple antigens, TriCAR vectors reduce the likelihood of antigen-negative escape variants, a common cause of relapse in traditional CAR-T therapies. This improved durability of response is a game-changer in the field of cancer immunotherapy.
Minimized Toxicity

TriCAR vectors exhibit greater precision in distinguishing between cancer cells and healthy tissue, minimizing off-target toxicity. This selectivity enhances patient safety and reduces the risk of adverse events.

Customization for Specific Needs

As a leading player in the CAR-T therapy industry, Creative Biolabs offers a range of customized services tailored to meet the unique needs of our clients. Our expertise in CAR-T vector design and development extends to:

Vector Selection: We help you choose the most suitable vector platform based on your specific requirements and target cells.
CAR Design and Optimization: Our team of experts specializes in designing CARs with enhanced specificity and functionality, ensuring optimal therapeutic outcomes.
Vector Production: We employ cutting-edge techniques to produce high-quality viral and non-viral vectors for CAR-T cell engineering.
Quality Control: Rigorous quality control measures are implemented to guarantee vector safety and efficacy.

We have developed a proprietary online system for customizing CAR and CAR cell products, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.

Reference

Guo, Zong Sheng, et al. "Bi-and tri-specific T cell engager-armed oncolytic viruses: next-generation cancer immunotherapy." Biomedicines 8.7 (2020): 204.